[The National Medical Insurance Administration announced a commercial bribery case involving medical institutions in the purchase and sale of medicines] September 13th. The National Medical Insurance Administration has established a pharmaceutical price and procurement credit evaluation system since August 2020 to guide pharmaceutical companies to operate with integrity and compliance, and to create a legal, compliant, fair and just pharmaceutical business environment. Analyzing the source information of commercial bribery cases in the field of pharmaceutical purchase and sales in the past three years, it was found that some medical institutions have loose and lax internal education management, and their staff have accepted commercial bribes from untrustworthy enterprises more frequently, in larger amounts, and for a longer period of time. Following the public exposure of a bribery case involving stent balloons by a Shanghai science and trade company, the Second Hospital of Hebei Medical University "received a kickback of 5,000 yuan for each stent". In the second half of 2025 alone, the hospital was involved in 9 judicial and criminal judgments. The staff of the hospital accepted commercial bribes 46 times, with the maximum amount involved in a single case being 16.58 million yuan, the longest duration being 11 years, and the cumulative amount involved being 184 million yuan.